Syndax
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before.
"As we strive to achieve our mission, we recognize the value that great people from a variety of backgrounds and experiences bring to our work. We are dedicated to recruiting talented, diverse individuals as a means of further enhancing our growing team.”
Michael Metzger President and COO
About our company
Syndax is a clinical stage biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer.
